Scholarlink

Introduction <p>Vitamin&#xa0;K antagonist (VKA) reversal is often required to prevent bleeding during urgent surgeries. This post&#xa0;hoc analysis evaluated the efficacy of four-factor prothrombin complex concentrate (4F-PCC) versus plasma for VKA reversal in a subgroup of patients requiring urgent orthopedic surgery.</p> Methods <p>A phase&#xa0;3b randomized controlled trial compared 4F-PCC with plasma for VKA reversal in patients aged ≥ 18&#xa0;years on VKA therapy with an international normalized ratio (INR) ≥ 2 needing urgent surgical or invasive interventions. This post hoc analysis evaluated the subgroup of patients undergoing urgent orthopedic surgery. The primary endpoints were hemostatic efficacy and rapid INR reduction. Secondary endpoints included time to INR correction (INR ≤ 1.3) and levels of vitamin&#xa0;K-dependent factors post infusion.</p> Results <p>Overall, 51 patients were included in the analysis. Excellent/good hemostatic efficacy was reported in 83.3% and 71.4% of&#xa0;patients receiving 4F-PCC and plasma, respectively (<i>p</i> = 0.39). Rapid INR reduction was achieved by 43.3% in the 4F-PCC group and 0.0% in the plasma group (<i>p</i> &lt; 0.001), with all vitamin&#xa0;K-dependent factors median activity levels being significantly higher in the 4F-PCC group up to 3&#xa0;h after the start of infusion. The median time to surgery was 5.8&#xa0;h and 19.2&#xa0;h for the 4F-PCC and plasma groups, respectively (<i>p</i> &lt; 0.001). There was no significant difference in the safety outcomes or mortality between the groups.</p> Conclusion <p>The use of 4F-PCC for urgent reversal of VKA therapy in patients needing urgent orthopedic surgery is effective and associated with rapid INR reduction and restoration of vitamin&#xa0;K-dependent factors. Compared with plasma, treatment with 4F-PCC also allows patients to undergo surgery earlier.</p> Trial Registration Number <p>ClinicalTrials. gov identifier,&#xa0;NCT00803101.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of Four-Factor Prothrombin Complex Concentrate Versus Plasma in Patients on Vitamin K Antagonists Undergoing Urgent Orthopedic Surgery: A Post Hoc Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月30日

查看全文
  • Michelle Kincaid,
  • Andrew J. Young,
  • Daniel Dybdahl,
  • Benjamin C. Taylor

摘要

Introduction

Vitamin K antagonist (VKA) reversal is often required to prevent bleeding during urgent surgeries. This post hoc analysis evaluated the efficacy of four-factor prothrombin complex concentrate (4F-PCC) versus plasma for VKA reversal in a subgroup of patients requiring urgent orthopedic surgery.

Methods

A phase 3b randomized controlled trial compared 4F-PCC with plasma for VKA reversal in patients aged ≥ 18 years on VKA therapy with an international normalized ratio (INR) ≥ 2 needing urgent surgical or invasive interventions. This post hoc analysis evaluated the subgroup of patients undergoing urgent orthopedic surgery. The primary endpoints were hemostatic efficacy and rapid INR reduction. Secondary endpoints included time to INR correction (INR ≤ 1.3) and levels of vitamin K-dependent factors post infusion.

Results

Overall, 51 patients were included in the analysis. Excellent/good hemostatic efficacy was reported in 83.3% and 71.4% of patients receiving 4F-PCC and plasma, respectively (p = 0.39). Rapid INR reduction was achieved by 43.3% in the 4F-PCC group and 0.0% in the plasma group (p < 0.001), with all vitamin K-dependent factors median activity levels being significantly higher in the 4F-PCC group up to 3 h after the start of infusion. The median time to surgery was 5.8 h and 19.2 h for the 4F-PCC and plasma groups, respectively (p < 0.001). There was no significant difference in the safety outcomes or mortality between the groups.

Conclusion

The use of 4F-PCC for urgent reversal of VKA therapy in patients needing urgent orthopedic surgery is effective and associated with rapid INR reduction and restoration of vitamin K-dependent factors. Compared with plasma, treatment with 4F-PCC also allows patients to undergo surgery earlier.

Trial Registration Number

ClinicalTrials. gov identifier, NCT00803101.